RESUMO
In this study, we tested the protective efficacy of recombinant Leishmania donovani iron superoxide dismutase B1 (SODB1) against Leishmania major infection in BALB/c mice. Mice were challenged with L. major 3weeks after the second boost immunization with rSODB1 alone or in the presence of adjuvants. Injection of BALB/c mice with rSODB1 alone elicited both humoral and cellular immune responses. Administration of rSODB1 with CpG ODN or GLA-SE (a synthetic toll-like receptor 4 agonist) adjuvant resulted in the induction of anti-SODB1 IgG1, and more importantly of significantly high levels of IgG2a isotype. Immunization of mice with rSODB1 alone or with adjuvant induced the production of IFN-γ by splenocytes in response to stimulation with L. major soluble leishmanial antigens (SLA). Moreover, immunization protocols involving rSODB1 resulted in a significant decrease in IL-10 as compared to controls. The presence of CpG ODN or GLA-SE adjuvant in the immunization protocols resulted in a relative increase in IFN-γ in response to stimulation with rSODB1 in comparison to immunization with rSODB1 alone. Mice immunized with rSODB1 plus CpG ODN or GLA-SE, were able to partially control their Leishmania infections, as indicated by the reduction in footpad swelling and parasite numbers, compared to controls. These results suggest that immunization with recombinant SODB1 protein together with CpG ODN or GLA-SE can be potential vaccine candidate against leishmaniasis.
Assuntos
Leishmania donovani/enzimologia , Leishmania donovani/imunologia , Leishmaniose Visceral/prevenção & controle , Vacinas Protozoárias , Superóxido Dismutase/imunologia , Receptores Toll-Like/imunologia , Adjuvantes Imunológicos/administração & dosagem , Animais , Anticorpos Antiprotozoários/biossíntese , Antígenos de Protozoários/imunologia , Feminino , Soros Imunes/imunologia , Imunidade Celular , Imunização Secundária , Imunoglobulina G/biossíntese , Interferon gama/biossíntese , Interleucina-10/biossíntese , Camundongos , Camundongos Endogâmicos BALB C , Vacinas Protozoárias/administração & dosagem , Vacinas Protozoárias/imunologia , Vacinas Protozoárias/normas , Distribuição Aleatória , Proteínas Recombinantes/imunologia , Organismos Livres de Patógenos Específicos , Baço/citologia , Baço/imunologia , Receptores Toll-Like/administração & dosagem , Receptores Toll-Like/agonistas , Vacinas SintéticasRESUMO
Activation of TLR4 by administration of LPS shortens the survival of skin allografts in mice treated with costimulation blockade through a CD8 T cell-dependent, MyD88-dependent, and type I IFN receptor-dependent pathway. The effect of TLR activation on the establishment of allogeneic hematopoietic chimerism in mice treated with costimulation blockade is not known. Using a costimulation blockade protocol based on a donor-specific transfusion (DST) and a short course of anti-CD154 mAb, we show that LPS administration at the time of DST matures host alloantigen-presenting dendritic cells, prevents the establishment of mixed allogeneic hematopoietic chimerism, and shortens survival of donor-specific skin allografts. LPS mediates its effects via a mechanism that involves both CD4(+) and CD8(+) T cells and results from signaling through either the MyD88 or the type I IFN receptor pathways. We also document that timing of LPS administration is critical, as injection of LPS 24 h before treatment with DST and anti-CD154 mAb does not prevent hematopoietic engraftment but administration the day after bone marrow transplantation does. We conclude that TLR4 activation prevents the induction of mixed allogeneic hematopoietic chimerism through type I IFN receptor and MyD88-dependent signaling, which leads to the up-regulation of costimulatory molecules on host APCs and the generation of alloreactive T cells. These data suggest that distinct but overlapping cellular and molecular mechanisms control the ability of TLR agonists to block tolerance induction to hematopoietic and skin allografts in mice treated with costimulation blockade.
Assuntos
Quimerismo , Transplante de Células-Tronco Hematopoéticas , Terapia de Imunossupressão , Isoantígenos/genética , Lipopolissacarídeos/administração & dosagem , Ativação Linfocitária/genética , Ativação Linfocitária/imunologia , Receptores Toll-Like/agonistas , Animais , Células Apresentadoras de Antígenos/imunologia , Células Apresentadoras de Antígenos/metabolismo , Transplante de Medula Óssea/imunologia , Linfócitos T CD8-Positivos/imunologia , Linfócitos T CD8-Positivos/metabolismo , Proteínas de Transporte/administração & dosagem , Sobrevivência de Enxerto/genética , Sobrevivência de Enxerto/imunologia , Terapia de Imunossupressão/métodos , Interferon Tipo I/biossíntese , Interferon Tipo I/metabolismo , Interferon Tipo I/fisiologia , Isoantígenos/imunologia , Isoantígenos/metabolismo , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Camundongos Knockout , Camundongos Transgênicos , Fator 88 de Diferenciação Mieloide/deficiência , Fator 88 de Diferenciação Mieloide/genética , Fator 88 de Diferenciação Mieloide/fisiologia , Poli I-C/administração & dosagem , Receptor de Interferon alfa e beta/deficiência , Receptor de Interferon alfa e beta/genética , Receptor de Interferon alfa e beta/fisiologia , Transdução de Sinais/genética , Transdução de Sinais/imunologia , Transplante de Pele/imunologia , Receptores Toll-Like/administração & dosagem , Receptores Toll-Like/metabolismoRESUMO
For many years, various cancer vaccines have been widely evaluated, however clinical responses remain rare. In this review, we attempt to address the question of which delivery strategies and platforms are feasible to produce clinical response and define the characteristics of the strategy that will induce long-lasting antitumor response. We limit our analysis and discussion to microparticles/nanoparticles, liposomes, heat-shock proteins, viral vectors and different types of adjuvants. This review aims to provide an overview of the specific characteristics, strengths and limitations of these delivery systems, focusing on their impacts on the development of melanoma vaccine. To date, only adoptive T-cell transfer has shown promising clinical outcomes compared to other treatments.
Assuntos
Vacinas Anticâncer/administração & dosagem , Melanoma/imunologia , Adenoviridae/genética , Adjuvantes Imunológicos/administração & dosagem , Animais , Vacinas Anticâncer/imunologia , Vetores Genéticos , Proteínas de Choque Térmico/administração & dosagem , Humanos , Lipossomos , Nanopartículas , Plasmídeos , Receptores Toll-Like/administração & dosagem , Vacinas de DNA/administração & dosagemRESUMO
Innate immune memory, also termed "trained immunity" in vertebrates, has been recently described in a large variety of plants and animals. In most cases, trained innate immunity is induced by pathogens or pathogen-associated molecular patterns (PAMPs), and is associated with long-term epigenetic, metabolic, and functional reprogramming. Interestingly, recent findings indicate that food components can mimic PAMPs effects and induce trained immunity. The aim of this study was to investigate whether bovine milk or its components can induce trained immunity in human monocytes. To this aim, monocytes were exposed for 24 h to ß-glucan, Toll-like receptor (TLR)-ligands, bovine milk, milk fractions, bovine lactoferrin (bLF), and bovine Immunoglobulin G (bIgG). After washing away the stimulus and a resting period of five days, the cells were re-stimulated with TLR ligands and Tumor necrosis factor (TNF-) and interleukin (IL)-6 production was measured. Training with ß-glucan resulted in higher cytokine production after TLR1/2, TLR4, and TLR7/8 stimulation. When monocytes trained with raw milk were re-stimulated with TLR1/2 ligand Pam3CSK4, trained cells produced more IL-6 compared to non-trained cells. Training with bIgG resulted in higher cytokine production after TLR4 and TLR7/8 stimulation. These results show that bovine milk and bIgG can induce trained immunity in human monocytes. This confirms the hypothesis that diet components can influence the long-term responsiveness of the innate immune system.
Assuntos
Imunidade Inata , Imunoglobulina G/administração & dosagem , Leite/imunologia , Monócitos/imunologia , Animais , Bovinos , Humanos , Interleucina-6/biossíntese , Lactoferrina/administração & dosagem , Leucócitos Mononucleares/imunologia , Ligantes , Lipopeptídeos/administração & dosagem , Receptores Toll-Like/administração & dosagem , Fator de Necrose Tumoral alfa/biossíntese , beta-Glucanas/administração & dosagemRESUMO
Cancer vaccines are designed to stimulate the body's immune system to kill tumor cells. To improve their immunogenicity, vaccine antigens must be combined with adjuvants which are able to stimulate the innate immunity and potentiate the adaptive immune response. In the last years a new generation of adjuvants mimicking the natural microbial ligands have been developed. In particular, several TLR ligands have been extensively explored as vaccine adjuvants and many preclinical and clinical studies have been conducted. However, the road to approval of such adjuvants for clinical use is still to go.
Assuntos
Adjuvantes Imunológicos/uso terapêutico , Vacinas Anticâncer/imunologia , Imunoterapia/métodos , Neoplasias/terapia , Receptores Toll-Like/imunologia , Imunidade Adaptativa , Animais , Vacinas Anticâncer/administração & dosagem , Humanos , Imunidade Inata , Imunogenicidade da Vacina , Ligantes , Camundongos , Neoplasias/imunologia , Receptores Toll-Like/administração & dosagemRESUMO
Cutaneous lupus erythematosus is a disfiguring and common manifestation in systemic lupus erythematosus, and the etiology of this predisposition for cutaneous inflammation is unknown. Here, we sought to examine the keratinocyte as an important source of IL-6 and define the mechanism for its increased production in cutaneous lupus erythematosus. Evaluation of discoid and subacute cutaneous lupus erythematosus lesions showed significant epidermal up-regulation of IL-6 compared with control via real-time PCR and immunohistochemistry. Keratinocytes from unaffected skin of lupus patients produced significantly more IL-6 compared with healthy control subjects after exposure to toll-like receptor 2, 3, or 4 agonists or exposure to UVB radiation. Pretreatment with type I interferons (IFN-α and IFN-κ) increased IL-6 production by control keratinocytes, and type I IFN blockade decreased IL-6 secretion by lupus keratinocytes. Secretion of keratinocyte-specific IFN-κ was significantly increased after toll-like receptor 2 and UVB treatment in lupus keratinocytes, and neutralization of IFN-κ decreased IL-6 production by lupus keratinocytes. Thus, lupus keratinocytes are primed for IL-6 hyperproduction in a type I IFN-dependent manner. Increased production of IFN-κ by lupus keratinocytes drives this response, indicating that IFN-κ may play a pathogenic role in cutaneous lupus erythematosus and serve as a target for treatment.
Assuntos
Interleucina-6/metabolismo , Queratinócitos/imunologia , Lúpus Eritematoso Cutâneo/imunologia , Lúpus Eritematoso Discoide/imunologia , Receptores Toll-Like/antagonistas & inibidores , Adulto , Biópsia por Agulha , Células Cultivadas , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Imuno-Histoquímica , Interleucina-6/imunologia , Queratinócitos/efeitos dos fármacos , Queratinócitos/metabolismo , Lúpus Eritematoso Cutâneo/patologia , Lúpus Eritematoso Discoide/patologia , Masculino , Pessoa de Meia-Idade , RNA/metabolismo , Reação em Cadeia da Polimerase em Tempo Real/métodos , Estudos de Amostragem , Estatísticas não Paramétricas , Receptores Toll-Like/administração & dosagem , Raios Ultravioleta/efeitos adversosRESUMO
BACKGROUND: The incidence of allergic rhinitis (AR) has increased constantly over the last decades. The disease can significantly lower quality of life and subsequently might progress to allergic asthma. Allergen-specific immunotherapy is mostly used to cope with the cause of the disease. However, incidence of systemic reactions or limited compliance hampers the widespread use of this therapeutic approach. Therefore, new candidates are examined to improve immunotherapy of allergies. Recently, a new technology was developed with the aim to positively influence the immune system of allergic patients. Virus-like particles (VLPs) represent a potent vaccine platform that has been proven to be immunogenic and clinically effective. To enhance immune cell activation, addition of Toll-like receptor ligands and/or depot-forming adjuvants seems to be helpful. In this context, CpG motifs represent intensive investigated and potent stimulators of T cells. This article focuses on the function of VLPs and CpG motifs and their clinical experience for treatment of AR. METHODS: A literature review was performed. RESULTS: Several published studies showed a beneficial impact of the treatment on allergic symptoms. They tested VLPs filled with or without CpG motifs in combination with or without allergen. CONCLUSION: Results encourage further investigations of VLPs and CpG motifs as adjuncts to or even alternative candidates for immunotherapy of allergic disorders.